An update on the safety of long-term vedolizumab use in inflammatory bowel disease.
Fiche publication
Date publication
août 2023
Journal
Expert opinion on drug safety
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Honap S, Netter P, Danese S, Peyrin-Biroulet L
Lien Pubmed
Résumé
Vedolizumab (Entyvio) is a humanized monoclonal antibody that disrupts the interaction between α4β7 integrin on circulating T-lymphocytes and MAdCAM-1 on the vascular endothelium to prevent their egress to sites of gut inflammation. It has proven therapeutic efficacy for the treatment of moderate-to-severe Crohn's disease, ulcerative colitis, and pouchitis.
Mots clés
Crohn’s disease, Inflammatory bowel disease, cancer, pregnancy, safety, surgery, ulcerative colitis, vedolizumab
Référence
Expert Opin Drug Saf. 2023 08 23;:1-10